Clover Health Investments Corp saw its stock lift sharply in morning trading after the Centers for Medicare & Medicaid Services (CMS) recalculated the insurer’s 2026 Medicare star rating to 4.5 stars, up from the prior 3.5-star score.
The upgrade applies to Contract H5141, Clover’s PPO Medicare Advantage plan, which covers more than 97% of the company’s members. CMS told Clover of the revised 4.5-star rating on June 9, following a federal court order that directed the agency to redo its calculation.
The legal victory traces back to a final judgment entered on May 29, 2026, by the U.S. District Court for the Southern District of Georgia. That judgment set aside Clover’s original 3.5-star rating and instructed CMS to recalculate the score in a manner consistent with the court’s order. The CMS notification on June 9 implemented the court-mandated revision.
Company management and investors view the upgraded rating as more than a reputational win. The 4.5-star result will feed directly into payment rates for 2027 and affect Clover’s eligibility for quality bonus payments from CMS. In combination with recent operational results, the adjustment has injected meaningful near-term financial momentum into Clover’s narrative.
On the fundamentals front, Clover reported its first-ever positive GAAP net income in the first quarter of 2026 and recorded a sharp year-over-year increase in revenue. Market analysts have reacted to the improving picture; Canaccord analyst Richard Close recently raised his price target for the stock while keeping a Buy rating, citing that gains across managed care are benefiting digital health companies.
The stock’s advance came even as broader market conditions were under pressure. The May 2026 consumer price index report, released the same morning, showed headline inflation accelerating to 4.2% year-over-year, the highest reading since 2023, with the rise attributed largely to a sharp jump in energy costs tied to geopolitical tensions. Core inflation was slightly below forecasts on a monthly basis, but the elevated headline number weighed on the overall market, with the S&P 500, Dow Jones, and NASDAQ trading lower during the session.
Despite the challenging macro backdrop, Clover bucked the broader decline. The stock was reported to have surged 13.2% in morning trading, and intraday market data showed an even larger move of about 14.57% at one point. Shares reached a new 52-week high of $5.01 during the session, reflecting the market’s positive reaction to the court-ordered CMS recalculation and the company’s recent financial results.
Investors will now be watching how the 4.5-star rating translates into payment flows in 2027 and how that interacts with Clover’s ongoing revenue and earnings trajectory. For now, the combination of a favorable legal ruling, a directly revenue-relevant quality upgrade, and an improving earnings profile helped CLOV move markedly higher while major indexes slipped.
Key points:
- The CMS recalculation raised Clover’s 2026 Medicare star rating to 4.5 from 3.5 for Contract H5141, covering over 97% of members.
- The rating change will directly affect 2027 payment rates, including qualification for quality bonus payments from CMS.
- Clover has reported its first positive GAAP net income in Q1 2026, with strong year-over-year revenue growth; an analyst recently raised the price target while keeping a Buy rating.
Risks and uncertainties:
- Broader market weakness driven by higher headline inflation weighed on major indexes the same day, which could limit gains despite company-specific news.
- The company’s upgraded rating applies to Contract H5141, which covers more than 97% of members, indicating concentration of the membership base under a single contract.